Abstract: Natural-KilleifT-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.

Abstract: Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition of IL-11-mediated signalling.

Abstract: A hip prosthesis device including a femoral stem, the femoral stem including an elongate stem sleeve having a blind hole extending in a longitudinal direction and a hole opening at an upper frontal end of the stem sleeve; a stem core having an elongate stem shaft inserted in the blind hole and slidable in the longitudinal direction, a neck having a lower neck portion and an upper neck portion, a lower end of a lower neck portion attached to an upper end of the stem shaft, the upper neck portion attachable to a femoral head; a shock absorber mechanism operatively provided between the stem shaft and the stem sleeve to act against a downwardly directed longitudinal sliding motion of the stem shaft relative to the stem sleeve; and a closure cap positioned to close the hole opening with a through hole which the neck extends with its lower neck portion.

Abstract: A method for assessing blood vessel stenosis using image data of a subject is disclosed. The image data represents a vascular structure of the subject. The method comprises: (a) segmenting, from the image data, a vessel segment representing a segment of a blood vessel, (b) obtaining, using the image data, a plurality of two-dimensional images of the vessel segment; said plurality of two-dimensional images representing respective cross-sections of the vessel segment, (c) identifying, for each of the plurality of two-dimensional images, a lumen area comprising lumen pixels representing a lumen of the corresponding cross-section, (d) obtaining a quantitative measure using the lumen areas of successive cross-sections of the vessel segment, and (e) assessing blood vessel stenosis using the quantitative measure. A computer system for performing the above method is disclosed.

Abstract: A method for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell transfer (ACT), is disclosed comprising: (i) analyzing a blood-derived sample obtained from the patient for one or more prognostic markers of long-term survival on treatment of a disease by ACT, and; (ii) based on the analysis of step (i), predicting whether the patient will be a long-term survivor on treatment of the disease by ACT. Also disclosed are methods for treating a patient by ACT, methods for selecting a patient for treatment by ACT, and methods for selecting a patient for treatment of a disease by ACT.

Abstract: The present invention relates to compounds comprising formula I: Amino Acid Sequence-(L)n-DMARD wherein the amino acid sequence comprises QKRAAYDQYGHAAFE-NH2 (SEQ ID NO: 1), DMARD is a disease modifying antirheumatic agent, L is a linker unit; —is a covalent bond and n is 0 or 1 and methods of using the compound for treatment of autoimmune diseases. In a preferred embodiment the DMARD is selected from Chloroquine and Hydroxychloroquine.

Abstract: The present disclosure provides a system and method of determining a risk score for triage. In particular, a system is provided for providing an assessment of risk of a cardiac event for a patient, for example an incoming patient to a hospital emergency department complaining of chest pain. In the disclosure, the system includes an input device for measuring physiological data based vital signs parameter of the patient, a twelve-lead electrocardiogram (ECG) device for establishing an ECG obtained from results of the electrocardiography procedure, and determining an ECG parameter and a heart rate variability (HRV) parameter therefrom. An ensemble-based scoring system is further provided, establishing weighted classifier based on past patient data and where the vital signs parameter, the ECG parameter and the HRV parameter are compared to corresponding weighted classifiers to determine a risk score. A corresponding method to determine a risk score for triage is also provided.

Abstract: The invention relates to topical injection in inflamed lesions or areas with liposomal corticosteroids.

Abstract: The present invention relates to a device for cardiac valve repair, the device comprising: at least one upstream anchoring means adapted to anchor to at least one tissue site, the tissue site located upstream with respect to a heart valve of a patient; and a coaptation structure arranged to extend from the upstream anchoring means, the coaptation structure comprising a free end, wherein the coaptation structure is operable to extend across the heart valve and locate the free end downstream from the heart valve and the coaptation structure operable to coapt with at least one heart valve leaflet of the patient's heart to prevent and/or minimize a backflow of blood. The present invention is suitable for the treatment of heart valves using minimally invasive approaches. Additionally, the present invention is directed to a method of implanting a device for cardiac valve repair in a patient's heart.

Abstract: This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hCENCs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed Peroxiredoxin-6 (Prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal endothelial cells from a mixture of cell.

Abstract: The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2???. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof.

Abstract: The present disclosure generally relates to an automated method and system for generating a panoramic visualization of a coronary arterial tree of a subject. The method comprises: acquiring an image volume of a thoracic cavity of the subject, the image volume providing a three-dimensional (3D) representation of the thoracic cavity; isolating a coronary structure in the 3D representation by abating one or more other anatomical structures in the thoracic cavity; abating one or more portions of the coronary structure in the 3D representation that attenuate visualization of the coronary arterial tree; generating, by maximum intensity projection (MIP), a plurality of MIP images of the coronary structure from the 3D representation; and compositing the MIP images to generate the panoramic visualization of the coronary arterial tree.

Abstract: A method is proposed for identifying an anatomical structure within a spatial-temporal image (i.e. a series of frames captured as respective times). A current frame of spatial-temporal medical image is processed using information from one or more previous and/or subsequent temporal frames, to aid in the segmentation of an object or a region of interest (ROI) in a current frame. The invention is applicable to both two- and three-dimensional spatial-temporal images (i.e., 2D+time or 3D+time), and in particular to cardiac magnetic resonance (CMR images). An initialization process for this method segments the left ventricle (LV) in a CMR image by a fuzzy c-means (FCM) clustering algorithm which employs a circular shape function as part of the definition of the dissimilarity measure.

Abstract: The present invention relates to methods for treating ischemic stroke including extension of the therapeutic time window for reperfusion. More particularly, the invention relates to a method of treating stroke in a subject by inhibiting the transient receptor potential melastatin 4 (TRPM4) channel. The present invention also provides uses of TRPM4 inhibitors, TRPM4 antibodies and kits for use in the methods of the invention.

Abstract: There is provided a computer-implemented method for controlling dispensing of at least one biologically active agent in intermittent doses over discrete predefined time periods, comprising the steps of: (i) initiating the dispensing of the biologically active agent in intermittent doses at a first background dosage rate; and (ii) adjusting to a background dosage rate according to the number of input signals received over each predefined time period from a signalling device.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: The present invention provides methods and agents for modulating WARS2 expression, WARS2 activity, or a combination thereof, thereby modulating angiogenesis. Also provided herein are methods for identifying individuals who could benefit from agents that modulate WARS2 expression, WARS2 activity, or a combination thereof.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.